Table 2.
Demographic and clinical data (mean ± standard deviation) split by H&Y stage.
| H&Y Stage | 1 | 2 | 3 | 4 |
|---|---|---|---|---|
| N (female) | 11 (5) | 26 (12) | 17 (9) | 14 (8) |
| Age (years) | 62 ± 10 | 62 ± 9 | 69 ± 5 | 76 ± 6 |
| Height (m) | 1.74 ± 0.11 | 1.74 ± 0.08 | 1.70 ± 0.10 | 1.70 ± 0.10 |
| MDS-UPDRS-III (0–132) | 13 ± 7 | 29 ± 11 | 34 ± 14 | 30 ± 13 |
| LEDD (mg/d) | 301 ± 187 | 368 ± 201 | 416 ± 282 | 608 ± 320 |
| On/Off (%) | 37/63 | 32/68 | 44/56 | 92/8 |
| MoCA (0–30) | 25.8 ± 3.0 | 26.3 ± 3.1 | 25.1 ± 3.5 | 23.7 ± 3.1 |
| PIGD (0–16) | 1.3 ± 1.0 | 2.4 ± 2.6 | 5.4 ± 1.9 | 8.5 ± 2.0 |
| Freezing (%) | 0 | 0 | 18 | 54 |
| Depressive symptoms (%) | 20 | 28 | 20 | 27 |
H&Y: Hoehn and Yahr; LEDD: Levodopa equivalent daily dose; MDS-UPDRS-III: Movement Disorder Society-revised version of the Unified Parkinson’s Disease Rating Scale, motor part; MoCA: Montreal Cognitive Assessment; PIGD: postural instability and gait difficulty.